Akums Drugs & Pharmaceuticals Ltd — Q4 FY26
Akums Drugs reported a strong Q4 FY26 with consolidated revenue of ₹1,158 crore (+9.7% YoY) and adjusted EBITDA of ₹152 crore (+61.6% YoY), driven by robust CDMO volume growth o...
bullish
high
✓ Verified against BSE filing
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q3 FY26
Q4 FY26 double-digit volume growth in CDMO
Management expects continued double-digit volume growth in CDMO for Q4 FY26 based on current visibility.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1